Cytosorbents Corp Files 8-K on Financials
Ticker: CTSO · Form: 8-K · Filed: Nov 7, 2024 · CIK: 1175151
| Field | Detail |
|---|---|
| Company | Cytosorbents CORP (CTSO) |
| Form Type | 8-K |
| Filed Date | Nov 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
CYTOSORBENTS FILES 8-K: FINANCIALS AND OPERATIONS UPDATE DUE NOV 7.
AI Summary
Cytosorbents Corporation filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This 8-K filing signals that Cytosorbents Corporation is providing updated financial information and operational details to the SEC, which is crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting event and does not inherently contain negative news or significant risk factors.
Key Players & Entities
- Cytosorbents Corporation (company) — Registrant
- November 7, 2024 (date) — Date of Report
- 305 College Road East Princeton, New Jersey 08540 (address) — Principal executive offices
FAQ
What specific financial results are being reported in this 8-K?
The provided text indicates the filing pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not detail the specific figures within this excerpt.
What is the significance of an 8-K filing for Cytosorbents Corporation?
An 8-K filing is a report of unscheduled material events or corporate changes that could be of importance to shareholders and the SEC, such as significant financial or operational updates.
When was this 8-K filed?
This 8-K was filed on November 7, 2024.
What is the principal executive office address for Cytosorbents Corporation?
The principal executive offices are located at 305 College Road East, Princeton, New Jersey 08540.
Does this filing indicate any changes in the company's structure or leadership?
The provided text does not specify any changes in structure or leadership; it focuses on reporting financial condition and operations.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-11-07 16:10:58
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value CTSO The Nasdaq Stock Marke
Filing Documents
- tm2427790d1_8k.htm (8-K) — 25KB
- tm2427790d1_ex99-1.htm (EX-99.1) — 353KB
- tm2427790d1_ex99-1img001.jpg (GRAPHIC) — 34KB
- 0001104659-24-115296.txt ( ) — 621KB
- ctso-20241107.xsd (EX-101.SCH) — 3KB
- ctso-20241107_lab.xml (EX-101.LAB) — 33KB
- ctso-20241107_pre.xml (EX-101.PRE) — 22KB
- tm2427790d1_8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operation and Financial Condition On November 7, 2024, CytoSorbents Corporation (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.*
01
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated November 7, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 7, 2024 CYTOSORBENTS CORPORATION By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: Chief Executive Officer